文献速递妇科肿瘤

Balstilimab联合Zalifrelimab双PD-1和CTLA-4检查点阻断用于晚期宫颈癌二线治疗:一项开放标签II期研究

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
PubMed 文献 · J Clin Oncol · 2021-12-21

该开放标签II期研究评估balstilimab(抗PD-1)联合zalifrelimab(抗CTLA-4)用于铂类治疗后复发和/或转移性宫颈癌患者,共155例女性入组治疗, efficacy可评估人群125例。确认的客观缓解率为25.6%(95% CI 18.8-33.9),中位随访21个月,缓解持续时间未达到,最常见免疫相关不良事件为甲状腺功能减退(14.2%)和甲状腺功能亢进(7.1%)。

要点

  • balstilimab 3 mg/kg每2周联合zalifrelimab 1 mg/kg每6周静脉给药,最长24个月。
  • 125例可评估患者确认ORR为25.6%(95% CI 18.8-33.9),含10例完全缓解和22例部分缓解。
  • PD-L1阳性肿瘤ORR为32.8%,PD-L1阴性为9.1%;鳞状细胞癌ORR为32.6%。

核心结论

  • 在复发和/或转移性宫颈癌患者中观察到有前景且持久的临床活性以及良好的耐受性,该试验是迄今评估双PD-1/CTLA-4阻断的最大规模试验。
  • balstilimab联合zalifrelimab在该场景中的进一步研究正在进行中。

研究设计与样本

  • 开放标签II期试验(ClinicalTrials.gov标识符:NCT03495882)。
  • 入组155例女性(中位年龄50岁,范围24-76岁),均为铂类治疗后复发的复发和/或转移性宫颈癌患者。
  • 125例基线有可测量病灶且晚期阶段仅接受过一线铂类治疗的患者构成疗效可评估人群。
  • 给药方案为balstilimab 3 mg/kg每2周一次联合zalifrelimab 1 mg/kg每6周一次静脉给药,最长24个月。
  • 主要终点为客观缓解率(ORR,RECIST版本1.1,独立中心审查评估);次要终点包括缓解持续时间、安全性和耐受性以及生存。

主要发现

  • 中位随访21个月,确认的ORR为25.6%(95% CI 18.8-33.9),包括10例完全缓解和22例部分缓解。
  • 中位缓解持续时间未达到,6、9、12个月缓解持续率分别为86.5%、75.5%和64.2%。
  • PD-L1阳性肿瘤患者ORR为32.8%,PD-L1阴性肿瘤患者ORR为9.1%。
  • 鳞状细胞癌患者ORR为32.6%。
  • 总体疾病控制率为52%(95% CI 43.3-60.6)。

关键数值与推荐

  • 确认的ORR为25.6%(95% CI 18.8-33.9),基于125例疗效可评估患者。
  • PD-L1阳性肿瘤ORR为32.8%,PD-L1阴性肿瘤ORR为9.1%。
  • 鳞状细胞癌患者ORR为32.6%。
  • 总体疾病控制率为52%(95% CI 43.3-60.6)。
  • 中位缓解持续时间未达到,6、9、12个月缓解持续率分别为86.5%、75.5%和64.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882) evaluated the combination of balstilimab plus zalifrelimab in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy. PATIENTS AND METHODS: Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, RECIST version 1.1, assessed by independent central review). Secondary end points included duration of response, safety and tolerability, and survival. RESULTS: In total, 155 women (median age, 50 years [range, 24-76 years]) were enrolled and treated with balstilimab plus zalifrelimab; 125 patients had measurable disease at baseline and one prior line of platinum-based therapy in the advanced setting, and these patients constituted the efficacy-evaluable population. The median follow-up was 21 months. The confirmed ORR was 25.6% (95% CI, 18.8 to 33.9), including 10 complete responders and 22 partial responders, with median duration of response not reached (86.5%, 75.5%, and 64.2% at 6, 9, and 12 months, respectively). The ORRs were 32.8% and 9.1% in patients with programmed death ligand-1-positive and programmed death ligand-1-negative tumors, respectively. For patients with squamous cell carcinoma, the ORR was 32.6%. The overall disease control rate was 52% (95% CI, 43.3 to 60.6). Hypothyroidism (14.2%) and hyperthyroidism (7.1%) were the most common immune-mediated adverse events. CONCLUSION: Promising and durable clinical activity, with favorable tolerability, was seen in this largest trial to date evaluating dual programmed death-1/cytotoxic T-lymphocyte-associated antigen-4 blockade in patients with recurrent and/or metastatic cervical cancer. Further investigation of the balstilimab and zalifrelimab combination in this setting is continuing.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Malley DM, Neffa M, Monk BJ, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2021. PMID: 34932394. doi:10.1200/JCO.21.02067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。